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Introduction
Predicting human pharmacokinetic (PK) profiles of novel drug candidates is critical in drug discovery and development to project dose, determine therapeutic index, and estimate drug-drug interaction (DDI) potential. With improved understanding on hepatic cytochrome P450 (CYP) activity, the relatively confident approaches have been developed in predicting hepatic CYPmediated small molecule clearance. These approaches have enabled the chemistry design to reduce CYP-mediated metabolism for a prolonged drug half-life. However, such efforts have also led to an increased prevalence of hepatic-transporter-mediated clearance, for which understanding is still limited as of today. As a result, for hepatic transporter substrates, even with reasonable estimates of hepatic CYP activity and volume of distribution, the systemic exposure may be mis-predicted due to a failure in predicting liver exposure elevated or lowered by transporters. In addition, the ability to accurately predict liver exposure is also a foundation for predicting pharmacodynamics (PD), DDI, and drug-induced toxicity within the liver.
Most approaches developed to predict exposures of transporter substrates are based on in vitro assays. Unfortunately, most in vitro transport rates cannot describe in vivo data without empirical scaling factors (i.e. fudge factors closing the gap between physiological prediction and clinical observation), whether with a physiologically based pharmacokinetic (PBPK) model, or static pharmacokinetic equations (Li et al., 2014a) . The empirical scaling factors are the primary limitations associated with approaches based on in vitro assays, because most published values are compound dependent and not readily available for novel compounds. Towards a prospective in vitro to in vivo extrapolation (IVIVE), Li et al. has developed an approach simultaneously leveraging data from multiple training compounds in empirical scaling factor estimation (e.g., global scaling factors that are not compound independent), assuming that substrates of the same This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on January 12, 2018 as DOI: 10.1124 at ASPET Journals on January 29, 2018 dmd.aspetjournals.org Downloaded from or similar transporters share the same scaling factor (Li et al., 2014b) . Animal studies are still an option for transporter substrates' PK predictions, particularly in understanding liver exposure, as global scaling factor estimations were based on systemic PK rather than liver concentration (Morse et al., 2015) . However, the use of traditional inter-species scaling over-simplifies the physiological differences among species, and direct measurement in terminal or biopsy studies to understand tissue concentrations can be ambiguous and potentially misleading due to improper data interpretation or species differences in tissue exposure.
Most, if not all, of the methods published so far are only validated by systemic exposure, mainly because of the challenges in acquiring human liver data. Positron emission tomography (PET) has been proposed as a way to monitor liver drug concentration (Shimizu et al., 2012) . However, PET studies are problematic due to being both expensive and to the fact that not all compounds can be easily prepared as PET ligands. Furthermore, PET signal can be confounded by metabolites formed in the liver (Li et al., 2014c) . For the few compounds with minimal hepatic metabolism, transporter activity either has minimal impact on liver exposure (e.g., metformin) or there are additional challenges in studying PK (e.g., enterohepatic recirculation for pravastatin). Hence, using human liver exposure data to easily validate prediction methods remains atypical.
In this study, bosentan, an organic anion-transporting polypeptide (OATP) substrate was chosen as a prototype compound to (1) understand its liver exposure through analysis on systemic exposure, and (2) develop an approach to prospectively predict its liver exposure. In the Part 1 published in a separate article, human liver exposure of bosentan has been estimated from its systemic exposure using a "deduction" method. With the deduced bosentan liver exposure, we can compare the accuracy of both established and novel approaches to predict systemic and liver exposure in Part 2.
This article has not been copyedited and formatted. The final version may differ from this version. 
Materials and Methods
Human and monkey hepatocyte uptake assay, and a mechanistic in vitro model
To understand the nonlinear transporter activity and intracellular binding processes, both sandwich cultured human hepatocyte (SCHH) and plated monkey hepatocyte (PMH) assays are performed with multiple dosing concentrations. The SCHH assay (lot HH1026, female donor, In Vitro ADMET, Columbia, MD) was carried out as described previously (Li et al., 2014c) , except that 1 mM rifamycin SV (RSV) was used as transporter inhibitor. The method for PMH assay (lot 10106012, In Vitro ADMET, Columbia, MD) is provided in the supplemental materials. 
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. , at zero based on a previous study (Bi et al., 2017) . Although RSV is usually used as a transporter inhibitor, in-house data show that at 1 mM, CYP-mediated metabolism is inhibited as well. In SCHH study, we could not detect any accumulation in the bile pocket, consistent with the clinical DMD # 78808 observation that minimal bosentan parent is identified in the feces following intravenous dosing (Weber et al., 1999) 
Ka,EC is the constant for extracellular non-specific binding. The amount of compound immobilized on the cell surface or plastic plate is assumed as the product of the total amount of extracellular compound and HEP, EC) . We assume that the immobilized compound not available for transport, will be mixed with the intracellular compound during cell lysis. In data fitting, the observed compound accumulation in the cell is represented as the sum of bound and unbound intracellular compound and the immobilized extracellular compound. Values of fixed parameters are listed in Table 1 , while values of other parameters are estimated by simultaneously fitting data generated with different dosing concentrations under different assay conditions (i.e. with and without transporter inhibitor and calcium).
All the mathematical models presented in this article are implemented in MATLAB 2016a Table S1 ). The binding kinetics in plasma and red blood cells (RBC) were estimated using data from in vitro assay (Supplemental Figure S1 ) and a model structure described in Part 1. The passive diffusion clearance between plasma and RBC were determined as described in Part 1. The binding kinetics in the liver tissue is assumed to be the same as that in the hepatocyte uptake assays. MichaelisMenten constant of hepatic active uptake (KM,liver,uptake) for monkey and rat were fixed at values determined from PMH and plated rat hepatocyte (PRH) studies. Michaelis-Menten constant of hepatic metabolism (KM,liver,metabolism) for monkey was fixed at a value determined from monkey hepatocyte stability assay, while this parameter for rat was determined by fitting in vivo data as in vitro data were not available. Parameters with fixed values are listed in Table 2 . For both species,
Michaelis-Menten constant of hepatic active basal efflux (KM,liver,efflux), rates for uptake, metabolism, and basal efflux (kliver,uptake, kliver,metabolism, kliver,efflux) , hepatic passive diffusion (Weber et al., 1996; Weber et al., 1999) and deduced liver exposure in Part 1 were used to validate predictions.
Method 1: prediction using human hepatocytes data. The values for CLliver,pass, kliver,uptake, and kliver,metabolism were predicted using in vitro hepatocyte clearance (or rate), physiological IVIVE scaling factors, and empirical IVIVE scaling factors. The physiological IVIVE scaling factor is the number of hepatocytes in the liver. The empirical IVIVE scaling factor is not available for the current model in a prospective prediction. Hence, they are approximated with the published values (Li et al., 2014b) . The published binding values in both plasma and liver are generally lower than values used in the current study (e.g., published bosentan plasma free fraction = 0.0053 versus 0.02 in the current study, and published intracellular free fraction = 0.018 versus around 0.036 in the current study). As such, to estimate "ball-park" values in our predictions, the uptake empirical scaling factor is scaled down by 4 fold (from 41 to 10.3), while metabolism and the passive , where α is an allometry exponent. To our knowledge, no similar prediction has been published for a transporter substrate before, hence α is arbitrarily fixed at 1. Similarly, kliver,uptake and kliver,metabolism are predicted to be 6.32×10 6 and 1.69×10 6 nmol•hour −1 . The hepatic basal efflux process cannot be confidently estimated from monkey in vivo data, as such this process is assumed to be zero in human prediction. Human Kpu scaler and ET binding parameters are assumed to be the same as monkey values (Table 3) .
Results
Hepatocyte uptake assay and mechanistic modeling
The observations and simulations for SCHH and PMH assays are provided in Figures 1 and 2 . In both SCHH and PMH data analyses, the kHEP,metabolism values are minimal. The active efflux transport process cannot be identified given the current data due to huge uncertainty in estimating KM,HEP,efflux. For binding parameters, PMH data are not sufficient to provide confident estimates;
hence, we assumed that PMH shared the same binding values as SCHH. All other parameters can be precisely determined (Table 1) . For comparison purposes, we also provided the published plated rat hepatocyte rates (Menochet et al., 2012) in Table 1 . It is worth noting that although ratios between kHEP,uptake and KM,HEP,uptake are both around 50 for SCHH and PMH, KM,HEP,uptake value is significantly smaller in PMH. In addition, PMH also has a small CLHEP,pass value.
Monkey and rat pharmacokinetic studies and mechanistic modeling
The model can reasonably describe the monkey ( Figure 3 ) and rat ( Figure 4 ) PK data in both plasma and liver samples. All monkey parameters except kliver,efflux and Km,liver,efflux can be confidently estimated (Table 3) , a similar phenomenon observed in fitting human data as described In the rat model, parameters for hepatic metabolism and efflux cannot be confidently identified (Table 3) . Kpuu and its 95% confidence intervals are 83. 4 (16, 130) It is worth noting that if the monkey PK data were not analyzed using the mechanistic model, but with a non-compartment analysis or a traditional two compartment model, the estimated blood clearance would be close to or greater than the blood flow in some dosing groups (Supplemental Table S2 ), due to ignoring nonlinearity in blood binding and study variabilities.
Prospectively predicting human systemic and liver pharmacokinetics with in vitro data, animal data, and mechanistic models
Both Method 1 (in vitro data based) and 2 (monkey data based) provide predictions that largely match the clinical PK data following intravenous dosing, but Method 2 provides a much more reasonable prediction, particularly in the distribution phase ( Figure 5 ). Using predicted hepatic processes from hepatocytes, the predicted human liver Kpuu is 142 for both 10 and 750 mg intravenous dosing ( Figure 5 ). Alternatively, utilizing monkey in vivo data predicted hepatic processes, the predicted human Kpuu is 21.1 and 22.9 for 10 and 750 mg intravenous dosing, which are much closer to the value (i.e. 34.9) we estimated with human clinical data in Part 1. The ability to estimate ET binding (particularly in vivo concentration of receptor) using Method 2 also contributes to a better systemic prediction (elimination phase), although liver predictions are similar with and without modeling ET binding.
Retrospective analyses on two prediction approaches
In addition to the prospective predictions described above, retrospective analyses were done to better understand IVIVE. In Method 1, the retrospective empirical scaling factors were backcalculated, as the ratios of hepatic processes values estimated in Part 1 using clinical data, to the physiologically scaled values based on hepatocyte data. The prospective empirical scaling factors we used were about 2-fold greater for kliver,uptake but 1.5 and 2 times lower for CLliver,pass and kliver,metabolism than the retrospective scaling factors (Table 4) . Using prospective scaling factors, the over-predicted uptake leads to under-predicted systemic concentration in the distribution phase, while under-predicted metabolism brings the systemic concentration back within the "normal" range during the elimination phase ( Figure 5 ). Although the two mis-predicted processes may cancel each other's impact upon systemic exposure, both will result in over-predicted liver exposure.
As to Method 1, we also calculated an empirical scaling factor for monkey and rat in retrospective analyses ( and kliver,uptake are provided, and we cannot determine if rat shares the same empirical scaling with human overall.
As to Method 2, even with the allometry exponent (α) arbitrarily fixed at 1, the model reasonably predicts systemic and liver exposure. To understand an α value that best describes the data, a retrospective calculation determined this value to be 0.88. The ratios between values of monkey and human rates are around 0.15 for all three hepatic processes (Table 3) , which makes it possible to use the same α across different hepatic processes in consistently translating monkey rates to human based on liver weights. Although human rates of hepatic processes were scaled from monkey in vivo values, Michaelis-Menten constants were still fixed at values from human hepatocyte assays. In the absence of in vitro hepatocyte data, these constants estimated from monkey in vivo data cannot accurately predict human pharmacokinetics (Supplemental Figure S2 ). 
Discussion
Prospectively predicting PK of hepatic transporter substrates in clinical studies remains a challenging task, particularly in predicting liver exposures. Although several approaches have been developed to face this challenge, most focus only on systemic exposure. In addition, due to the use of compound-dependent empirical scaling factors estimated by fitting clinical observation, these published works are more retrospective analyses but rarely tested prospectively. Similarly, when predicting liver-exposure-driven DDI and toxicity of transporter substrates, most published approaches allow floating parameters in order to match clinical observations. Hence, the confidence in using these approaches in real world drug discovery and development is low.
There are two obstacles impeding progress: (1) comprehensive knowledge of human transporter activity, and (2) human liver exposure data to valid prediction approaches developed. The former problem is a result of the latter. Without direct measurement of the liver, researchers can only use indirect surrogates in most studies (e.g., systemic exposure as a surrogate of metabolism, or PK of a victim compound as a surrogate of DDI). Unfortunately, for most compounds, the relationship between the liver exposure and these surrogates is not well understood. Hence, sometimes even a retrospective analysis on clinical observations may not yield a confident result, let alone a prospective prediction.
In this study, we aimed to (1) understand human liver exposure of bosentan, a transporter substrate;
and (2) compound with hepatic metabolism like bosentan, the deduction approach seems to currently be the only viable one to predict liver exposure. The two key criteria for such an approach are accuracy and precision: confidence in accuracy resides in the conservation of mass, while the precision is tested with statistical approaches. Unlike most other hepatic transporter substrates, bosentan does not have additional disposition pathways, such as biliary excretion and enterohepatic recirculation, simplifying the problem in analyzing mass conservation through PBPK modeling. Although challenges in modeling bosentan PK exist (e.g., potentially non-linear binding processes), they can still be studied with in vitro assays. In addition, there are sufficient clinical data to generate precise parameter estimates and liver predictions, which make bosentan unique from other compounds that have been studied previously (Li et al., 2016) . Both advantages help to more confidently establish a relationship among hepatic disposition, exposure, and their systemic surrogate.
In Part 2, several approaches using readily available preclinical tools were tested against the liver exposure deduced in Part 1. Direct liver measurements in terminal animal studies were tested first.
Even species with great similarity to human, their liver exposures can be quite different from human's (e.g., Kpuu of about 60 in monkey but about 35 in human for bosentan).
As to mechanistic approaches, although they use the same model structure, and can both describe the systemic exposure, the newly proposed Method 2 (i.e. hepatic processes rates estimated using monkey data) shows a more accurate prediction. As for predicting liver exposure, Method 1 (i.e.
hepatic process rates estimated using hepatocyte data) leads to a liver Kpuu of 142, which is substantially greater than the value (34.9) deduced using clinical data. Conversely, Kpuu from Method 2 is more consistent with the deduced value. A set of parameter values that can reasonably simulate systemic exposure or clearance cannot necessarily predict liver exposure due to estimated by fitting systemic data, and used to simulate liver exposure, or PD, DDI, toxicity driven by it. The details about this topic have been addressed in a previous publication (Li et al., 2016) .
In Method 1, the prospective empirical scaling factors leading to over-predicted hepatic uptake were estimated in a previous study by simultaneously fitting human systemic PK of several OATP substrates (Li et al., 2014b) . The approach was developed to reduce uncertainty in estimating scaling factors by fitting data of individual compounds. There are multiple reasons that may lead to a mis-match between the current prediction and the old scaling factors. These scaling factors are developed with a model assuming linear kinetics, while the current model uses nonlinear equations to describe both binding and hepatic processes. In addition, in vitro SCHH assays were performed with different hepatocyte lots in the two studies, which may have different transporter activity. It should not be concluded that Method 1 is necessarily worse than Method 2 at this time.
If the global scaling factor was re-estimated with the current model structure and hepatocyte lots, Method 1 might yield improved systemic and liver predictions. In estimating empirical scaling factors by simultaneously fitting clinical data of several compounds, there are also areas deserving further studies. For example, Kpu for non-liver tissues are usually fixed at values from in silico approaches (Rodgers and Rowland, 2006) . The scaling factor estimation can be confounded if nonliver Kpu is inaccurate for any training compound (Li et al., 2014b; Li et al., 2014c ). We have partly tested another topic: for the same compound, can we estimate empirical scaling factor from animal and apply them to human (Watanabe et al., 2009 )? Based on our retrospective analysis (Table 4) , the values of scaling factors for human and animal can be quite different for compounds like bosentan.
This article has not been copyedited and formatted. The final version may differ from this version. Due to the lack of empirical scaling factors specifically tailored for the current model structure and hepatocyte, we have not fully tested the liver prediction capability of Method 1. From this perspective, Method 2 may be a superior approach since it does not require data from other training compounds, although its prediction accuracy should be further validated with additional compounds in future. Method 2 requires data from both in vivo monkey studies (for hepatic process rates) and in vitro studies (for Michaelis-Menten constants). We have tested prediction without in vitro data, where both rates and Michaelis-Menten constants are estimated using in vivo monkey data. However, the systemic exposure is under-predicted while liver exposure is over-predicted. A similar phenomenon has been published previously with another acidic compound with a molecular weight of 428 (i.e. a potential OATP substrate), GSK269984A. Although rates may be similar between two species, monkey may have a smaller KM,liver,uptake value than human, which may cause over-predicted uptake. Hence, unless it has been proven that the compounds have large
enough KM values in both monkey and human, hepatic processes estimated from monkey in vivo data per se should not be used to predict human PK without accounting for species KM difference.
We have also tried to use Method 2 but with hepatic rates, Kpu scaler and ET binding parameters estimated from rat in vivo data. An allometry exponent of 0.8 seems to best describe the human data, however the simulation still over-predicts liver exposure but under-predictes systemic exposure (Supplemental Figure S3) . It worth noting that we do not have confidently estimated
Michaelis-Menten constants from in vitro assays for rat, hence the estimated rat in vivo hepatic rates and potentially other fitted rat parameters are not confident either, which may contribute to the mis-prediction.
In conclusion, using bosentan data, we have provided an example for prospectively predicting hepatic exposure of a transporter substrate. The accuracies of the new and previously established shows the highest accuracy in this study.
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VHEP,EC mL per well 0.5 (fixed) 0.5 (fixed) PRH data are published in a previous study (Menochet et al., 2012) . Median and confidence interval are not provided for the parameters with high uncertainty (i.e. the range of approximated confidence interval is greater than 20 magnitude). The globally optimized value is provided instead.
